相关实验视频

Updated: May 11, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

CD5免疫活性与胸腺癌的总体存活时间较长有关:简要报告

Julia R Naso^1,2,3, Sarah M Jenkins⁴, Julie A Vrana¹

¹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

JTO clinical and research reports

|April 17, 2025

概括

CD5免疫组织化学染色显示,作为胸腺癌的预后标志物具有前景. 胸腺癌细胞中 CD5 染色阳性与显著更长的整体存活率有关,这表明其潜在的临床实用性.

科学领域:

在瘤学瘤学.
病理学病理学病理学

背景情况:

胸腺癌是具有不同预后的侵袭性癌症.
确定可靠的预后标志物对于患者管理至关重要.

研究的目的:

评估特定免疫组织化学标志物的预后意义,包括 CD5,在胸腺癌.
为了确定CD5染色是否可以预测胸腺癌患者的整体存活率.

主要方法:

对36个胸膜癌样本进行了免疫组织化学检查.
追溯收集的生存数据是追溯收集的.
统计分析评估了标记物表达与整体存活率之间的关联.

主要成果:

在36%的病例中观察到阳性CD5染色 (≥50%的瘤细胞).
阳性CD5染色与较长的整体存活时间显著相关 (HR=0.18,p=0.005).
对于CD5阳性病例,三年生存率为100%,而CD5阴性病例为48%,独立于其他因素.

结论:

CD5免疫组织化学可以作为胸腺癌的新预后标志物.
这一发现可能有助于进行风险分层和治疗决定,用于胸膜恶性瘤.

关键词:

CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 CD5 免疫组织化学免疫组织化学病理学病理学病理学预测预后预测预测幸存的生存方式胸腺癌 (thymic carcinoma) 是一种癌症.

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.